Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function
Clinical Pharmacology in Drug Development · 2024-04 · 13 (4) · 410-418
DOI: 10.1002/cpdd.1371 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 04.02.2024. Verfasst von Mason W Freeman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Computational and Integrative Biology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Baxdrostat is a selective small‐molecule aldosterone synthase inhibitor in development for treatment of hypertension and chronic kidney disease. This phase 1, open‐label, parallel‐group study assessed the safety and pharmacokinetics (PK) of baxdrostat in participants with varying degrees of renal function. Participants were enrolled into control (estimated glomerular filtration rate [eGFR] ≥60 mL/min), moderate to severe renal impairment (eGFR 15‐59 mL/min), or kidney failure (eGFR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Computational and Integrative Biology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- CinCor Pharma, Inc., Waltham, MA, USA.
- CinRx Pharma, LLC, Cincinnati, OH, USA.
Zitieren
APA
Freeman, M. W., Halvorsen, Y. D., Bond, M., Murphy, B., & Isaacsohn, J. (2024). Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function. Clinical Pharmacology in Drug Development, 13(4), 410-418. https://doi.org/10.1002/cpdd.1371
Vancouver
Freeman MW, Halvorsen YD, Bond M, Murphy B, Isaacsohn J. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function. Clinical Pharmacology in Drug Development. 2024;13(4):410-418. doi:10.1002/cpdd.1371
BibTeX
@article{Freeman2024,
author = {Freeman, Mason W and Halvorsen, Yuan-Di and Bond, Mary and Murphy, Brian and Isaacsohn, Jonathan},
title = {Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {4},
pages = {410--418},
doi = {10.1002/cpdd.1371}
}
EUVIMED